Page last updated: 2024-12-05

sulfathiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfathiazole is a sulfonamide antibiotic that was first synthesized in 1940. It is effective against a wide range of bacteria, including those that cause pneumonia, meningitis, and urinary tract infections. Sulfathiazole works by inhibiting the synthesis of dihydrofolic acid, an essential coenzyme for bacterial growth. It is important to note that sulfathiazole can cause allergic reactions in some individuals. Due to the development of newer antibiotics with fewer side effects, sulfathiazole is now rarely used.'

Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5340
CHEMBL ID437
CHEBI ID9337
SCHEMBL ID94165
MeSH IDM0046785

Synonyms (259)

Synonym
AC-12783
smr000017368
MLS002154174
NCGC00016309-09
NCGC00016309-10
BB 0245015
BRD-K14705039-001-05-7
norsulfasol
sulzol
2-sulfonamidothiazole
streptosilthiazole
wln: t5n csj bmswr dz
sulfathiazol
thiozamide
cerazole
cerazol (suspension)
poliseptil
chemosept
n(sup1)-(2-thiazolyl)sulfanilamide
azoseptale
azoquimiol
sulfanilamidothiazole
benzenesulfonamide, 4-amino-n-2-thiazolyl-
rp 2090
wintrazole
formosulfathiazole
eleudron
2090 r.p.
norsulfazole
estafilol
usaf sn-9
septozol
thiacoccine
nsc-31812
thiasulfol
m&b 760
neostrepsan
sulfocerol
n(sup1)-2-thiazolylsulfanilamide
dulana
thiazamide
sulfanilamide, n(sup1)-2-thiazolyl-
coco-thiazole
2-sulfanilamidothiazole
2-(sulfanilylamino)thiazole
sulfanilamide, n1-2-thiazolyl-
ciba 3714
nsc31812
sanotiazol
planomide
norsulfazol
2-(p-aminobenzenesulfonamido)thiazole
duatok
cibazol
DIVK1C_000560
KBIO1_000560
NCI60_002730
SDCCGMLS-0065585.P001
SPECTRUM_001000
BPBIO1_000057
PRESTWICK_430
cas-72-14-0
NCGC00016309-01
sulphathiazole
sulfathiazolum
sulfthiazole
n(1)-2-thiazolylsulfanilamide
4-amino-n-2-thiazolylbenzenesulfonamide
2-sulfanilamidothiazol
4-amino-n-1,3-thiazol-2-ylbenzenesulfonamide
CHEBI:9337 ,
sulfatiazol
2-(p-aminobenzenesulphonamido)thiazole
PRESTWICK2_000016
BSPBIO_000051
OPREA1_105970
OPREA1_297844
BSPBIO_003378
[(4-aminophenyl)sulfonyl]-1,3-thiazol-2-ylamine
nsc683531
4-amino-n-thiazol-2-yl-benzenesulfonamide
SPECTRUM5_001441
PRESTWICK3_000016
IDI1_000560
NCGC00091133-01
AB00052102
sulfanilamide, n(sup 1)-2-thiazolyl-
sulfathiazol [inn-french]
n(sup 1)-2-thiazolylsulfanilamide
caswell no. 809b
norsulfazolum
sulfanilamide, n(1)-2-thiazolyl-
nsc 31812
ccris 765
einecs 200-771-5
epa pesticide chemical code 077903
solfatiazolo [dcit]
m+b 760
nsc 683531
2-sulfanilamidothiazol [german]
sulfatiazol [inn-spanish]
2090 rp
ai3-01050
sulfathiazolum [inn-latin]
hsdb 4380
sulfamul
72-14-0
sulfathiazole
nsc-683531
sulfathiazole (usp/inn)
D01047
NCGC00091133-03
NCGC00091133-02
KBIOSS_001480
KBIO2_001480
KBIOGR_000755
KBIO2_006616
KBIO3_002598
KBIO2_004048
NINDS_000560
SPECTRUM4_000348
SPBIO_000821
SPBIO_001972
SPECTRUM2_000841
SPECTRUM3_001729
PRESTWICK0_000016
PRESTWICK1_000016
SPECTRUM1500553
NCGC00091133-04
4-amino-n-(1,3-thiazol-2-yl)benzenesulfonamide
STK043870
HMS2092K09
AKOS000108630
sulfathiazole (triple sulfa)
triple sulfa (sulfathiazole)
CHEMBL437 ,
HMS501L22
2-(4-aminobenzenesulfonamido)thiazole
n-2-thiazolylsulfanilamide
HMS1921C07
HMS1568C13
cid_5340
bdbm50027796
NCGC00016309-02
HMS2095C13
ytz ,
unii-y7fks2xwqh
solfatiazolo
sulfathiazole [usp:inn:ban]
y7fks2xwqh ,
NCGC00257187-01
dtxsid8026068 ,
tox21_303238
dtxcid606068
tox21_202243
NCGC00259792-01
4-amino-n-(1,3-thiazol-2-yl)benzene-1-sulfonamide
pharmakon1600-01500553
nsc-757331
nsc757331
tox21_110363
n1-2-thiazolylsulfanilamide
4-amino-n-(thiazol-2-yl)benzenesulfonamide
HMS2259A13
CCG-40296
NCGC00016309-07
NCGC00016309-06
NCGC00016309-08
NCGC00016309-03
NCGC00016309-04
NCGC00016309-05
n1-(2-thiazolyl)sulfanilamide
pyridine,2-(chloromethyl)-3,4-dimethoxy-
F1443-4816
FT-0631310
sulfathiazole [ep monograph]
gyne-sulf component sulfathiazole
sulfathiazole [mart.]
sulfathiazole [inn]
sulfathiazole [usp monograph]
sulfathiazole component of vagilia
sulfathiazole component of sultrin
sulfathiazole [green book]
sulfathiazole component of trysul
sulfathiazole [hsdb]
sulfathiazole [vandf]
sulfathiazole [usp-rs]
trysul component sulfathiazole
sulfathiazole [mi]
triple sulfa (sulfathiazole) [orange book]
sulfathiazole component of gyne-sulf
sulfathiazole [who-dd]
vagilia component sulfathiazole
sultrin component sulfathiazole
859037-27-7
sulfathiazole [orange book]
EPITOPE ID:122234
S3116
DB06147
HY-B0507
SCHEMBL94165
n'-(2-thiazolyl)sulfanilamide
4-amino-n-(thiazol-2-yl)-benzenesulfonamide
tox21_110363_1
cambridge id 5251400
Q-201765
sulfathiazole, antibiotic for culture media use only
4-[(1,3-thiazol-2-yl)aminosulfonyl]aniline
sulfavitina
sulfanilamide, n1-4-thiazolin-2-ylidene-
enterobiocine
cerazol
n-1-2-thiazolylsulfanilamide
2-sulfathiazole
4-amino-n-(1,3-thiazol-2-yl)benzenesulfonamide #
AB00052102_15
AB00052102_14
4-amino-n-(2-thiazolyl)benzenesulfonamide
mfcd00005319
sr-05000001722
SR-05000001722-3
sulfathiazole, vetranal(tm), analytical standard
sulfathiazole, united states pharmacopeia (usp) reference standard
HMS3652A03
SR-05000001722-1
sulfathiazole, european pharmacopoeia (ep) reference standard
sulfathiazole, analytical standard, >=98.0%
sulfathiazole 100 microg/ml in acetonitrile
sulfathiazole; 4-amino-n-(thiazol-2-yl)benzenesulfonamide
SBI-0051527.P004
NCGC00016309-14
HMS3712C13
SW149625-4
Q408427
gtpl12699
DS-17245
sulfathiazole-13c6
BRD-K14705039-001-08-1
AMY33440
D70411
benzenesulfonamide, 4-amino-n-2-thiazolyl
benzenesulfonamide, 4 amino n 2 thiazolyl
4-amino-n-2-thiazolyl benzenesulfonamide
sulfathiazole 1000 microg/ml in acetonitrile
EN300-18132
sulfathiazolum (inn-latin)
n(sup1)-2-thiazoylsulfanilamide
sulfathiazole (usp-rs)
sulfatiazolo
sulfathiazole (usp monograph)
sulfatiazol (inn-spanish)
sulfathiazole (ep monograph)
sulfathiazole (usp:inn:ban)
sulfathiazol (inn-french)
sulfathiazole (mart.)
j01eb07
d06ba02
sulfaplex
Z57198680

Research Excerpts

Overview

Sulfathiazole (STZ) is a widely used sulfonamide antibiotic. Its residues have negative impacts on soil.

ExcerptReferenceRelevance
"Sulfathiazole (STZ) is a widely used sulfonamide antibiotic, while its residues have negative impacts on soil."( Remediation of sulfathiazole contaminated soil by peroxymonosulfate: Performance, mechanism and phytotoxicity.
Ding, M; Nie, M; Nie, S; Qiu, L; Wu, L; Yan, C; Zhang, Y, 2022
)
1.8

Effects

ExcerptReferenceRelevance
"Sulfathiazole has been the subject of numerous publications through which considerable confusion about the morphic form is apparent."( Determination of the onset of crystallization of N1-2-(thiazolyl)sulfanilamide (sulfathiazole) by UV-Vis and calorimetry using an automated reaction platform; subsequent characterization of polymorphic forms using dispersive Raman spectroscopy.
Anderson, JE; Moore, S; Tarczynski, F; Walker, D, 2001
)
1.26

Compound-Compound Interactions

ExcerptReferenceRelevance
" The enhanced in vitro biological properties of the drug-drug salt hydrate may be attributed to the higher extent of its supersaturation with respect to the individual components, which leads to higher diffusion rates."( A Drug-Drug Salt Hydrate of Norfloxacin and Sulfathiazole: Enhancement of in Vitro Biological Properties via Improved Physicochemical Properties.
Desiraju, GR; Ganguly, S; Gopi, SP, 2016
)
0.7

Bioavailability

ExcerptReferenceRelevance
" Bioavailability from these two types of suspensions was studied from urinary free drug excretion."( Bioavailability of sulfathiazole from flocculated and deflocculated suspensions and its implications.
Gudsoorkar, VR; Rambhau, D; Rao, YM,
)
0.46
" The drug is very poorly absorbed since the minimum effective concentration in plasma was not attained at any time following oral administration."( Deposition kinetics, metabolism and urinary excretion of sulfathiazole following oral administration in sheep.
Hapke, HJ; Jain, SK, 1995
)
0.54
" The drug is poorly absorbed into the circulation after intraruminal administration since the levels in plasma could not reach up to minimum effective therapeutic concentration at any time."( In vitro metabolism of sulfathiazole in rumen fluid and its metabolism and disposition kinetics following intraruminal administration in sheep.
Hapke, HJ; Jain, SK, 1995
)
0.6
"Formulations containing amorphous active pharmaceutical ingredients (APIs) present great potential to overcome problems of limited bioavailability of poorly soluble APIs."( A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron, V; Corrigan, OI; Healy, AM; Tajber, L, 2011
)
0.59
"Water-soluble prodrug strategy is a practical alternative for improving the drug bioavailability of sparingly-soluble drugs with reduced drug efficacy."( Novel prodrugs with a spontaneous cleavable guanidine moiety.
Hamada, Y, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" A problem is that the (in-vivo) rate of absorption cannot be directly measured and for that reason, it is frequently substituted by evaluation of the (in-vitro) dissolution."( In-Vivo Analysis and Model-Based Prediction of Tensides' Influence on Drug Absorption.
Babinec, A; Murgaš, J; Pavlovičová, J; Tárník, M; Vitko, A; Vitková, Z, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" the total 14C-residues in the gastrointestinal tract six hours after dosing increased, but decreased in other tissues."( The effect of nitrite on 14C-sulphathiazole (4-amino-N-2-thiazolyl[U-14C]benzenesulphonamide) metabolism in the rat.
Feil, VJ; Nelson, PA; Paulson, GD, 1987
)
0.27
" The results showed that microwave technology can be employed in the design of solid dosage forms for controlled-release application without the use of noxious chemical agents."( Design of controlled-release solid dosage forms of alginate and chitosan using microwave.
Chan, LW; Kho, SB; Sia Heng, PW; Wong, TW, 2002
)
0.31
" The catalytic rate was increased with Fe(3)O(4)/HA dosage and H(2)O(2) concentration."( Humic acid coated Fe3O4 magnetic nanoparticles as highly efficient Fenton-like catalyst for complete mineralization of sulfathiazole.
Cai, Y; Meng, Z; Niu, H; Zhang, D; Zhang, S; Zhang, X, 2011
)
0.58
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Solid-state characterisation of a drug following pharmaceutical processing and upon storage is fundamental to successful dosage form development."( Modification of the solid-state nature of sulfathiazole and sulfathiazole sodium by spray drying.
Bianco, S; Caron, V; Corrigan, OI; Healy, AM; Hu, Y; Nolan, L; Tajber, L, 2012
)
0.64
"Depending on their concentrations the surface-active substances, tensides (surfactants) can positively or negatively influence the drug absorption, which is widely used in the design of the dosage forms with controlled release."( In-Vivo Analysis and Model-Based Prediction of Tensides' Influence on Drug Absorption.
Babinec, A; Murgaš, J; Pavlovičová, J; Tárník, M; Vitko, A; Vitková, Z, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
EC 2.5.1.15 (dihydropteroate synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
1,3-thiazoles
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
substituted aniline
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
thyroid hormone biosynthesis524

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.56230.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.23870.004023.8416100.0000AID485290
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency69.00830.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.58960.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.61310.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.87240.000229.305416,493.5996AID743075
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9 precursorHomo sapiens (human)Potency10.00000.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.82490.000323.4451159.6830AID743066
heat shock protein beta-1Homo sapiens (human)Potency58.29290.042027.378961.6448AID743210; AID743228
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency10.00000.00638.235039.8107AID883
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)75.90800.10000.10000.1000AID652151
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)75.90800.10000.10000.1000AID652151
Dihydropteroate synthaseEscherichia coli K-12IC50 (µMol)2.50002.50003.60004.7000AID55870
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)2.50000.00040.908610.0000AID55870
Transcriptional activator protein LasRPseudomonas aeruginosa PAO1IC50 (µMol)9.00000.11003.15839.0000AID1414075
Endothelin-1 receptorHomo sapiens (human)IC50 (µMol)69.00000.00000.76479.9000AID66341
Endothelin-1 receptorRattus norvegicus (Norway rat)IC50 (µMol)69.00000.00001.774610.0000AID66057
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (135)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
response to xenobiotic stimulusDihydropteroate synthaseEscherichia coli K-12
folic acid biosynthetic processDihydropteroate synthaseEscherichia coli K-12
folic acid-containing compound biosynthetic processDihydropteroate synthaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydropteroate synthaseEscherichia coli K-12
folic acid biosynthetic processDihydropteroate synthaseEscherichia coli K-12
mitotic cell cycleEndothelin-1 receptorHomo sapiens (human)
branching involved in blood vessel morphogenesisEndothelin-1 receptorHomo sapiens (human)
response to hypoxiaEndothelin-1 receptorHomo sapiens (human)
in utero embryonic developmentEndothelin-1 receptorHomo sapiens (human)
blood vessel remodelingEndothelin-1 receptorHomo sapiens (human)
response to amphetamineEndothelin-1 receptorHomo sapiens (human)
regulation of heart rateEndothelin-1 receptorHomo sapiens (human)
glomerular filtrationEndothelin-1 receptorHomo sapiens (human)
cardiac chamber formationEndothelin-1 receptorHomo sapiens (human)
left ventricular cardiac muscle tissue morphogenesisEndothelin-1 receptorHomo sapiens (human)
atrial cardiac muscle tissue developmentEndothelin-1 receptorHomo sapiens (human)
cardiac neural crest cell migration involved in outflow tract morphogenesisEndothelin-1 receptorHomo sapiens (human)
noradrenergic neuron differentiationEndothelin-1 receptorHomo sapiens (human)
intracellular calcium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
mitochondrion organizationEndothelin-1 receptorHomo sapiens (human)
signal transductionEndothelin-1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
activation of adenylate cyclase activityEndothelin-1 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin-1 receptorHomo sapiens (human)
respiratory gaseous exchange by respiratory systemEndothelin-1 receptorHomo sapiens (human)
regulation of blood pressureEndothelin-1 receptorHomo sapiens (human)
cell population proliferationEndothelin-1 receptorHomo sapiens (human)
response to woundingEndothelin-1 receptorHomo sapiens (human)
gene expressionEndothelin-1 receptorHomo sapiens (human)
protein kinase A signalingEndothelin-1 receptorHomo sapiens (human)
regulation of glucose transmembrane transportEndothelin-1 receptorHomo sapiens (human)
neural crest cell fate commitmentEndothelin-1 receptorHomo sapiens (human)
artery smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
neuron remodelingEndothelin-1 receptorHomo sapiens (human)
heparin metabolic processEndothelin-1 receptorHomo sapiens (human)
thyroid gland developmentEndothelin-1 receptorHomo sapiens (human)
cellular response to oxidative stressEndothelin-1 receptorHomo sapiens (human)
embryonic heart tube developmentEndothelin-1 receptorHomo sapiens (human)
aorta developmentEndothelin-1 receptorHomo sapiens (human)
vasoconstrictionEndothelin-1 receptorHomo sapiens (human)
norepinephrine metabolic processEndothelin-1 receptorHomo sapiens (human)
middle ear morphogenesisEndothelin-1 receptorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin-1 receptorHomo sapiens (human)
cellular response to human chorionic gonadotropin stimulusEndothelin-1 receptorHomo sapiens (human)
enteric nervous system developmentEndothelin-1 receptorHomo sapiens (human)
sympathetic nervous system developmentEndothelin-1 receptorHomo sapiens (human)
axon extensionEndothelin-1 receptorHomo sapiens (human)
embryonic skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
neuromuscular processEndothelin-1 receptorHomo sapiens (human)
sodium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin-1 receptorHomo sapiens (human)
face developmentEndothelin-1 receptorHomo sapiens (human)
axonogenesis involved in innervationEndothelin-1 receptorHomo sapiens (human)
establishment of endothelial barrierEndothelin-1 receptorHomo sapiens (human)
pharyngeal arch artery morphogenesisEndothelin-1 receptorHomo sapiens (human)
renal sodium ion absorptionEndothelin-1 receptorHomo sapiens (human)
calcium ion transmembrane transportEndothelin-1 receptorHomo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEndothelin-1 receptorHomo sapiens (human)
cellular response to luteinizing hormone stimulusEndothelin-1 receptorHomo sapiens (human)
protein transmembrane transportEndothelin-1 receptorHomo sapiens (human)
glomerular endothelium developmentEndothelin-1 receptorHomo sapiens (human)
podocyte differentiationEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathway involved in heart processEndothelin-1 receptorHomo sapiens (human)
renal albumin absorptionEndothelin-1 receptorHomo sapiens (human)
vascular associated smooth muscle cell developmentEndothelin-1 receptorHomo sapiens (human)
mesenchymal cell apoptotic processEndothelin-1 receptorHomo sapiens (human)
sympathetic neuron axon guidanceEndothelin-1 receptorHomo sapiens (human)
semaphorin-plexin signaling pathway involved in axon guidanceEndothelin-1 receptorHomo sapiens (human)
podocyte apoptotic processEndothelin-1 receptorHomo sapiens (human)
meiotic cell cycle process involved in oocyte maturationEndothelin-1 receptorHomo sapiens (human)
cranial skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
response to acetylcholineEndothelin-1 receptorHomo sapiens (human)
regulation of protein localization to cell leading edgeEndothelin-1 receptorHomo sapiens (human)
positive regulation of cation channel activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
developmental pigmentationEndothelin-1 receptorHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein arginine N-methyltransferase 6Homo sapiens (human)
base-excision repairProtein arginine N-methyltransferase 6Homo sapiens (human)
regulation of mitochondrion organizationProtein arginine N-methyltransferase 6Homo sapiens (human)
methylationProtein arginine N-methyltransferase 6Homo sapiens (human)
protein modification processProtein arginine N-methyltransferase 6Homo sapiens (human)
regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein arginine N-methyltransferase 6Homo sapiens (human)
cellular senescenceProtein arginine N-methyltransferase 6Homo sapiens (human)
regulation of signal transduction by p53 class mediatorProtein arginine N-methyltransferase 6Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processProtein arginine N-methyltransferase 6Homo sapiens (human)
peptidyl-arginine methylation, to asymmetrical-dimethyl arginineProtein arginine N-methyltransferase 6Homo sapiens (human)
chromatin remodelingProtein arginine N-methyltransferase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
dihydropteroate synthase activityDihydropteroate synthaseEscherichia coli K-12
transferase activityDihydropteroate synthaseEscherichia coli K-12
metal ion bindingDihydropteroate synthaseEscherichia coli K-12
phosphatidylinositol phospholipase C activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor activityEndothelin-1 receptorHomo sapiens (human)
protein bindingEndothelin-1 receptorHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
chromatin bindingProtein arginine N-methyltransferase 6Homo sapiens (human)
protein bindingProtein arginine N-methyltransferase 6Homo sapiens (human)
histone arginine N-methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
protein-arginine N-methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
protein-arginine omega-N monomethyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
protein-arginine omega-N asymmetric methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
histone methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
histone bindingProtein arginine N-methyltransferase 6Homo sapiens (human)
histone H4R3 methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
histone H3R2 methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
histone H2AR3 methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
histone H3 methyltransferase activityProtein arginine N-methyltransferase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmDihydropteroate synthaseEscherichia coli K-12
cytosolDihydropteroate synthaseEscherichia coli K-12
cytosolDihydropteroate synthaseEscherichia coli K-12
plasma membraneEndothelin-1 receptorHomo sapiens (human)
plasma membraneEndothelin-1 receptorHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 6Homo sapiens (human)
nucleoplasmProtein arginine N-methyltransferase 6Homo sapiens (human)
nucleolusProtein arginine N-methyltransferase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (198)

Assay IDTitleYearJournalArticle
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID534110Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1852916Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate and measured by malachite green based colorimetric assay relative to control2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1764064Antibacterial activity against Enterococcus faecalis assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1764072Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID1764073Antibacterial activity against Escherichia coli ATCC 25922 assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID649900Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1764065Antibacterial activity against Staphylococcus aureus assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID649895Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID66057Antagonism of [125 I]ET-1 binding to the rat endothelin receptor in vascular smooth muscle VSM-A10 cells.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID650055Selectivity ratio of IC50 for human HepG2 cell sto MIC90 for Staphylococcus aureus CCM 4516/082012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1187272Antibacterial activity against Escherichia coli RCMB 010052 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1278488Antibacterial activity against Staphylococcus aureus at 10 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1187266Antibacterial activity against Staphylococcus aureus RCMB 010028 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID649901Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1764071Antibacterial activity against Acinetobacter baumannii assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID1278491Antibacterial activity against Proteus sp. at 50 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID649902Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1852929Redox activity of compound assessed as redox index at 1 uM measured by resazurin assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1187268Antibacterial activity against Salmonella typhimurium RCMB 010072 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1890854Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1852923Aqueous stability of the compound at pH 7.4 measured after 60 mins by spectrophotometric analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1890853Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID534107Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1852919Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured by FRET assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1286842Inhibition of N-terminal hexa-His tagged human PRMT6 expressed in Sf9 cells using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1890860Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1764067Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID1852931Thiol reactivity of compound measured by TNB2- assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID534108Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1852920Inhibition of recombinant SARS-CoV-2 3CLpro expressed in Escherichia coli NiCo21(DE3) assessed as residual activity at 500 uM using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins in presence of 1mM DTT followed by substrate addition and2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID649907Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1852917Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins in presence of 1 mM DTT followed by substrate addition and measured by malachite green based colori2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID649909Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID649896Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1890857Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1852924Redox activity of compound assessed as redox index at 100 uM measured by HRP-PR assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1278490Antibacterial activity against Pseudomonas aeruginosa at 50 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1852922Inhibition of recombinant Escherichia coli DdlB assessed as residual activity at 500 uM using D-alanine as substrate incubated for 20 mins and measured by malachite green based colorimetric assay relative to control2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID409955Inhibition of mouse liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1278492Antibacterial activity against Staphylococcus aureus at 50 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1852930Thiol reactivity of compound at 100 uM measured by DTNB assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID55870In vitro inhibition of dihydropteroate synthase from Escherichia coli.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Monocyclic pteridine analogues. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1852927Redox activity of compound assessed as redox index at 100 uM in presence of 100 uM TCEP measured by H2DCFDA assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1890856Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1187267Antibacterial activity against Escherichia coli RCMB 010052 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1764068Antibacterial activity against Klebsiella pneumonia assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID649897Antimycobacterial activity against isoniazid-, rifampicin-, ofloxacin-, ethambutol-resistant Mycobacterium avium 330/88 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID534106Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1187273Antibacterial activity against Salmonella typhimurium RCMB 010072 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID649906Antibacterial activity against methicillin-resistant Staphylococcus aureus H 5996/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1764066Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID534111Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID649894Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID670244Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID649904Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1890852Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1187264Antibacterial activity against Streptococcus pneumoniae RCMB 010010 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1890861Antibacterial activity against Acinetobacter baumannii assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID650056Selectivity ratio of IC50 for human HepG2 cell sto MIC90 for methicillin-resistant Staphylococcus aureus H 5996/082012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID534112Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm19802008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID649893Selectivity ratio of IC50 for human HepG2 cell sto MIC100 for Mycobacterium kansasii 235/802012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1764070Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID1852926Redox activity of compound assessed as redox index at 100 uM measured by H2DCFDA assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID649905Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID409953Inhibition of mouse liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID649908Antibacterial activity against methicillin-resistant Staphylococcus epidermidis H 6966/08 after 24 hrs by broth microdilution method2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1852921Inhibition of Mycobacterium tuberculosis MetAP1a assessed as residual activity at 625 uM using L-methionine 7-amido-4-methylcoumarin as fluorogenic substrate and measured by fluorescence based assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1764063Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID228124Enzymatic activity was determined1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
Parasite enzymes as potential targets for antiparasitic chemotherapy.
AID649903Antimycobacterial activity against Mycobacterium kansasii 6509/96 after 21 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1278486Antibacterial activity against Pseudomonas aeruginosa at 10 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1278487Antibacterial activity against Proteus sp. at 10 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1890858Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1278485Antibacterial activity against Escherichia coli at 10 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1852915Inhibition of recombinant Escherichia coli MurA assessed as residual activity at 500 uM using UDP-N-acetylglucosamine as substrate preincubated for 30 mins followed by substrate addition and measured by malachite green based colorimetric assay relative to2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID649898Antimycobacterial activity against Mycobacterium kansasii 235/80 after 7 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1852925Redox activity of compound assessed as redox index at 100 uM in presence of 1 mM DTT measured by HRP-PR assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1278496Antibacterial activity against Staphylococcus aureus at 100 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1278489Antibacterial activity against Escherichia coli at 50 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1764078Antibacterial activity against methicillin-resistant Staphylococcus aureus measured after 13 passages by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID1278481Antibacterial activity against Staphylococcus aureus at 1 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID649899Antimycobacterial activity against Mycobacterium kansasii 235/80 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1764069Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as bacterial growth inhibition by broth microdilution method2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.
AID64418Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1187269Antibacterial activity against Streptococcus pneumoniae RCMB 010010 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1187271Antibacterial activity against Staphylococcus aureus RCMB 010028 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1890855Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID534109Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm05272008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID649892Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 after 14 days2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1278495Antibacterial activity against Proteus sp. at 100 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1278494Antibacterial activity against Pseudomonas aeruginosa at 100 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1414075Inhibition of LasR in Pseudomonas aeruginosa harboring GFP-fused quorum sensing lasB measured every 15 mins up to 12 hrs by GFP reporter gene assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Pseudomonas aeruginosa Quorum Sensing Systems as Drug Discovery Targets: Current Position and Future Perspectives.
AID650054Selectivity ratio of IC50 for human HepG2 cell sto MIC100 for Mycobacterium kansasii 6509/962012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1187265Antibacterial activity against Enterococcus faecalis RCMB 010068 at 100 umol/ml after 24 hrs by well diffusion assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1187270Antibacterial activity against Enterococcus faecalis RCMB 010068 after 24 hrs by twofold serial dilution technique2014European journal of medicinal chemistry, Oct-06, Volume: 85Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1278493Antibacterial activity against Escherichia coli at 100 ug/ml by disc diffusion method2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Metal-based biologically active azoles and β-lactams derived from sulfa drugs.
AID650057Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 18 hrs by alamar blue assay2012European journal of medicinal chemistry, Apr, Volume: 50Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.
AID1852928Redox activity of compound assessed as redox index at 10 uM measured by resazurin assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145687Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID66341Inhibitory concentration against Endothelin A receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Selective optimization of side activities: another way for drug discovery.
AID1890859Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth measured after 24 hrs by CLSI based broth microdilution method2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (610)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990440 (72.13)18.7374
1990's24 (3.93)18.2507
2000's47 (7.70)29.6817
2010's82 (13.44)24.3611
2020's17 (2.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.54 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index138.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (78.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.61%)5.53%
Reviews10 (1.52%)6.00%
Case Studies2 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other640 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]